Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Premkumar Reddy
Icahn School of Medicine at Mount Sinai, Department: Internal Medicine/medicine
Should you be removed from our database? Contact us at [email protected]. Read more below.
Onconova Therapeutics
Equity Interest - Non-publicly traded entity ( e.g., stock, stock option, or other ownership interest)
Dr. Premkumar Reddy (the Principal Investigator in this study) receives financial compensation as a consultant for Onconova Therapeutics (a biopharmaceutical company which holds the license for the compounds used in this study).
Dr. Reddy is a named inventor on various issued and pending patents related to novel cancer treatments which are filed by Temple University and licensed to Onconova. Dr. Reddy receives royalties relating to these patents.
Dr. Reddy also owns equity in and serves on the Board of Directors of Onconova. Compounds that are used in this study were patented jointly by Temple University and Mount Sinai School of Medicine and licensed to Onconova. Commercialization of these compounds would benefit Onconova, Temple University and Mount Sinai School of Medicine.
Utility of RAS mimetics to block oncogenic signaling in colorectal cancer
PROJECT NARRATIVE Colorectal cancer is the second leading cause of cancer-associated deaths worldwide. Since 45% of CRCs harbor a mutation in the K-RAS gene, targeting its activity constitutes an important and rational approach to treat these tumors. This application describes experiments aimed at testing the effects of RAS mimetics, rigosertib and 015040 that target RAS-signaling, on CRCs using genetically modified and PDX models, with a long term goal of conducting clinical trials in patients.
Filed on March 14, 2018.
Tell us what you know about Premkumar Reddy's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Premkumar Reddy filed other conflict of interest disclosures with the NIH:
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Premkumar Reddy | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Onconova Therapeutics | $150,000 - $199,999 |
| Premkumar Reddy | Icahn School of Medicine at Mount Sinai | Conflict of Interest | Onconova Therapeutics | $10,000 - $19,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.